Abstract
Lixia Wang1,*, Xiantao Ye1,*, Xingming Cai2,*, Jingna Su1, Renqiang Ma3, Xuyuan Yin1, Xiuxia Zhou1, Huabin Li2,3, Zhiwei Wang1
1The Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou, China
2Department of Geriatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3Department of ENT, Head and Neck Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*These authors have contributed equally to this work
Correspondence to:
Zhiwei Wang, e-mail: [email protected]
Huabin Li, e-mail: [email protected]
Keywords: curcumin, Skp2, glioma, growth, invasion
Received: March 23, 2015 Accepted: May 11, 2015 Published: May 23, 2015
ABSTRACT
Studies have demonstrated that curcumin exerts its tumor suppressor function in a variety of human cancers including glioma. However, the exact underlying molecular mechanisms remain obscure. Emerging evidence has revealed that Skp2 (S-phase kinase associated protein 2) plays an oncogenic role in tumorigenesis. Therefore, we aim to determine whether curcumin suppresses the Skp2 expression, leading to the inhibition of cell growth, invasion, induction of apoptosis, and cell cycle arrest. To this end, we conducted multiple methods such as MTT assay, Flow cytometry, Wound healing assay, invasion assay, RT-PCR, Western blotting, and transfection to explore the functions and molecular insights of curcumin in glioma cells. We found that curcumin significantly inhibited cell growth, suppressed cell migration and invasion, induced apoptosis and cell cycle arrest in glioma cells. Furthermore, we observed that overexpression of Skp2 promoted cell growth, migration, and invasion, whereas depletion of Skp2 suppressed cell growth, migration, and invasion and triggered apoptosis in glioma cells. Mechanistically, we defined that curcumin markedly down-regulated Skp2 expression and subsequently up-regulated p57 expression. Moreover, our results demonstrated that curcumin exerts its antitumor activity through inhibition of Skp2 pathway. Collectively, our findings suggest that targeting Skp2 by curcumin could be a promising therapeutic approach for glioma prevention and therapy.
INTRODUCTION
Glioma is one of the common primary brain tumors in adults. Due to its aggressive growth and invasion, the median survival is generally less than one and half years from the time of diagnosis [1]. Even in the favorable situations, most patients with glioma die within two years [1]. This high lethality could be due to that surgery cannot remove entire tumor without harming health brain. Standard treatment with temozolomide and radiotherapy has increased the median overall survival by 15–20 months [2]. However, chemotherapy treatment needs to overcome the blood-brain barrier and drug resistance. Despite progress in glioma therapy regimens such as surgery, radiation, chemotherapy, or combined modalities, the prognosis for malignant glioma patients remains dismal [3]. Thus, it is necessary to discover new potential therapeutic agents for the clinical studies.
A growing body of evidence implicates that curcumin, a golden pigment extracted from turmeric, exhibits pleiotropic activities such as antioxidant, anti-inflammatory, antiviral, antifungal, antibacterial, anti-diabetic, and neuroprotective properties [4]. Moreover, many studies have demonstrated that curcumin exerts its anti-tumor activity in a broad spectrum of human cancers including glioma [5–8]. For example, it has been reported that curcumin inhibited cell proliferation via targeting the Wnt/β-catenin signaling pathway in medulloblastoma [9]. Moreover, Du et al. found that curcumin inhibited SHH (sonic hedgehog)/Gli1 signaling pathway, leading to inhibition of cell growth and induction of apoptosis in vitro and in vivo in glioma [10]. Further study showed that curcumin exerted its antitumor activity involved in reactivation of RANK (receptor activator of nuclear factor κB) and inactivation of STAT3 (signal transducer and activator of transcription 3) in glioblastoma cells [11]. Notably, curcumin synergistically enhanced paclitaxel-mediated cell growth inhibition in glioma cells [12]. Additionally, curcumin was discovered to suppress the cell growth through inhibition of HADC4 (histone deacetylase 4) and NF-κB (nuclear factor kappa-B) pathways in medulloblastoma cells [13, 14]. Although many studies have revealed the molecular basis of curcumin-induced cell growth inhibition, the underlying molecular mechanisms have not been fully elucidated.
Skp2 (S-phase kinase associated protein 2) as a key oncoprotein has been characterized to play an oncogenic role in tumorigenesis [15–19]. Skp2 belongs to the ubiquitin proteosome system and exerts its oncogenic functions via degradation of its ubiquitination targets such as p21 [20], p27 [21], p57 [22], E-cadherin [23], and FOXO1 (forkhead box O1) [24]. Overexpression of Skp2 has been identified and is associated with poor prognosis in various types of human cancers [25, 26]. Lin et al. reported that Akt interacts with and directly phosphorylates Skp2, leading to promotion of cell proliferation and tumorigenesis [27]. This group also found that targeting Skp2 suppressed tumorigenesis through Arf-p53-independent cellular senescence [28]. Our previous study has shown that Skp2 is acetylated by p300 and subsequently promoted its cytoplasmic retention, which enhanced cell migration through degradation of E-cadherin [23, 29]. Chan et al. reported that the Skp2-SCF (Skp, cullin, F-box containing complex) E3 ligase activated Akt ubiquitination, herceptin sensitivity and tumorigenesis [30]. This group further identified that inhibition of Skp2-SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression [31]. These studies indicate that inactivation of Skp2 could be a promising approach for treating human cancers [32].
In the current study, we determined whether overexpression of Skp2 promoted cell growth, migration and invasion, but induced cell apoptosis and cell cycle arrest. Moreover, we explored whether curcumin exhibits its anticancer activity via inactivation of Skp2 in glioma cells. Our results demonstrated that Skp2 was critically involved in glioma tumorigenesis and that curcumin down-regulated the expression of Skp2, resulting in upregulation of p57 and down-regulation of pAkt, which could lead to inhibition of tumorigenesis. Our findings suggest that curcumin could be a potential efficient agent for the treatment of glioma.
RESULTS
Curcumin inhibited cell proliferation
To detect whether curcumin treatment inhibits cell growth in glioma cells, MTT assay was used to measure the growth viability in U251 and SNB19 cells treated with different concentrations of curcumin for 48 hours and 72 hours, respectively. As expected, we found that curcumin significantly inhibited cell growth in time- and dose-dependent manner in both U251 and SNB19 cells (Figure 1A). The IC50 that caused 50% inhibition of cell growth at 72 hours for both glioma cell lines was found to around 15 μM (Figure 1A). Therefore, we used 15 μM curcumin in the following studies.
Curcumin induced apoptosis
It has been known that curcumin-mediated cell growth inhibition could be due to the increased apoptosis. Thus, we further explored whether curcumin could trigger apoptosis in glioma cells. To achieve this goal, we detected the effects of curcumin treatment on apoptotic cell death using PI-FITC-annexin assay. U251 and SNB19 cells were treated with 10, 15 μM curcumin for 48 hours. After treatment, we measured the cell apoptosis and observed that the induction of cell apoptosis by curcumin treatment was dose-dependent (Figure 1B), suggesting that curcumin treatment led to apoptosis in glioma cells.
Curcumin induced cell cycle arrest
To further define the anti-tumor effect of curcumin on glioma cells, we conducted the cell cycle analysis by PI staining and flow cytometry in U251 and SNB19 cells treated with 15 μM curcumin for 48 hours. We identified a typical G2/M arrest pattern from 7% with control to 24% with curcumin treatment in U251 cells (Figure 1C). Similarly, curcumin treatment caused G2/M arrest in SNB19 cells (Figure 1C). These results showed that curcumin distinctly caused G2/M phase arrest in glioma cells.
Curcumin inhibited cell migration and invasion
To dissect whether curcumin inhibited the motility of the cells, we conducted the wound healing assay using scratch approach and invasion assay using matrigel-coated membrane. Our wound healing assay demonstrated that curcumin significantly decreased cell migration in both U251 and SNB19 cells (Figure 2A and 2B). Consistent with this result, curcumin treatment led to decreased penetration of glioma cells via the matrigel-coated membrane compared with the control cells (Figure 2C). Altogether, curcumin has anti-invasive function in glioma cells.
Figure 1: Effect of curcumin on cell growth, apoptosis, and cell arrest. A. Effect of curcumin on cell growth in glioma cells was detected by MTT assay. *P < 0.05, compared to the control. B. Cell apoptosis in glioma cells treated with curcumin was determined by Flow cytometry. C. Curcumin induced glioma cell cycle arrest.
Figure 2: Curcumin inhibited cell migration and invasion on glioma cells. A–B. The inhibitory effect of curcumin on glioma cell migration was detected using wound healing assay in U251 cells (A, left panel) and SNB19 cells (B, left panel). Right panel, Quantitative results are illustrated for left panels. *P < 0.05, vs control. C. Top panel, the inhibitory effect of curcumin on glioma cell invasion was detected by Transwell chambers assay. Bottom panel, Quantitative results are illustrated for Top panel. *P < 0.05, **P < 0.01 vs control.
Curcumin decreased Skp2 expression
Emerging evidence has revealed that Skp2 exerts its oncogenic functions in tumorigenesis. To determine the molecular mechanism of curcumin-mediated anti-tumor activities, we measured the expression of Skp2 at mRNA and protein levels in glioma cells treated with curcumin. Our real-time RT-PCR analysis results demonstrated that Skp2 mRNA levels were markedly decreased in U251 and SNB19 cells after curcumin treatment (Figure 3A). More importantly, our Western blotting analysis showed that curcumin also down-regulated the Skp2 protein level in both glioma cells (Figure 3B and 3C). To further validate the inactivation of Skp2 by curcumin could impact on Skp2 downstream target genes such as pAkt and p57, we detected the expression of pAkt and p57 in glioma cells with curcumin treatment. We found that curcumin down-regulated the expression of pAkt and p57 in both U251 and SNB19 cells (Figure 3B and 3C). Taken together, curcumin exerts its anti-tumor activity through down-regulation of Skp2 signaling pathway.
Over-expression of Skp2 decreased curcumin-induced cell growth inhibition
To determine whether curcumin exhibits its anti-tumor activity partly through down-regulation of Skp2 in glioma cells, U251 cells and SNB19 cells were transfected with Skp2 cDNA or empty vector as control. We observed that over-expression of Skp2 promoted cell growth in both glioma cell lines (Figure 4A). Moreover, over-expression of Skp2 rescued cell growth inhibition by curcumin treatment in U251 cells and SNB19 cells (Figure 4A), suggesting that curcumin-mediated cell growth inhibition could be in part due to down-regulation of Skp2. These results suggest that curcumin exerts its biological function via inactivation of Skp2 in glioma cells.
Over-expression of Skp2 enhanced glioma cell motility
Next, we explored whether Skp2 could control cell motility in glioma cell lines. The results from our wound healing assay showed that over-expression of Skp2 caused increased numbers of cells migrating across the wound (Figure 4B). Consistently, our invasion assay showed that Skp2 promoted cell invasion in both glioma cells (Figure 4C). Strikingly, over-expression of Skp2 in combination with curcumin treatment led to lower numbers of migrated and invasive cells compared with curcumin treatment alone (Figure 4B and 4C). Next, we found that overexpression of Skp2 abrogated activation of p57 by curcumin (Figure 5A and 5B). These results provide evidence that curcumin exhibits anti-tumor activity through regulation of Skp2 and its target gene p57.
Down-regulation of Skp2 by siRNA promotes curcumin-induced cell growth inhibition and apoptosis
In line with the oncogenic role of Skp2, we found that the down-regulation of Skp2 expression significantly inhibited cell growth induced by curcumin (Figure 6A). Skp2 siRNA transfected cells were significantly more sensitive to spontaneous and curcumin-induced apoptosis (Figure 6B). Notably, we identified that depletion of Skp2 suppressed migration and invasion in glioma cells (Figure 6C and 6D). More importantly, depletion of Skp2 in combination with curcumin treatment retarded cell migration and invasion to a greater degree compared with curcumin alone or siRNA treatment alone (Figure 6C and 6D). Our results also showed that Skp2 siRNA inhibited pAkt activity and increased p57 expression; however, curcumin plus Skp2 siRNA inhibited pAkt activity and increased p57 expression to more degree compared to curcumin alone or siRNA transfection alone (Figure 7A–7D).
Figure 3: Curcumin downregulated Skp2 expression at RNA and protein levels. A. The Skp2 mRNA expression was detected using RT-PCR in glioma cells treated with curcumin. *P < 0.05, **P < 0.01 vs control. B–C. Left panel, the expression of Skp2, pAkt and p57 was determined by western blotting analysis in U251 (B) and SNB19 cells (C) after curcumin treatment. Right panel, Quantitative results are illustrated for left panel. *P < 0.05, **P < 0.01, compared to the control.
Figure 4: The effect of Skp2 overexpression on cell growth, migration and invasion. A. MTT assay was used to detect the effect of Skp2 overexpression in combination with curcumin treatment on glioma cell proliferation. *P < 0.05, **P < 0.01, compared with control; #P < 0.05 compared with curcumin treatment or Skp2 cDNA transfection. B. Left panel, The wound healing assay was conducted to detect the cell migration in glioma cells after Skp2 cDNA transfection and curcumin treatment. cDNA: Skp2 cDNA; cDNA+Curcumin: Skp2 cDNA+Curcumin. Right panel, Quantitative results are illustrated for left panel. C. Left panel, Invasion assay was performed in glioma cells after Skp2 cDNA transfection and curcumin treatment. Right panel, Quantitative results are illustrated for left panel.
Figure 5: The expression of Skp2 and p57 was measured in Skp2 cDNA transfected glioma cells treated with curcumin. A–B. Left panel: The expression of Skp2 and its target p57 was detected by western blotting in glioma cells with Skp2 cDNA transfection and curcumin treatment. Right panel: Quantitative results are illustrated for left panel. *P < 0.05, **P < 0.01, compared with control; #P < 0.05 compared with curcumin treatment or Skp2 cDNA transfection.
Figure 6: The effect of Skp2 downregulation on cell growth, apoptosis, migration, and invasion. A. MTT assay was used to detect the effect of skp2 siRNA in combination with curcumin treatment on glioma cell proliferation. Both: curcumin + Skp2 siRNA. *P < 0.05, compared with control; #P < 0.05 compared with curcumin treatment or Skp2 siRNA transfection. B. Apoptosis was detected by Flow cytometry in glioma cells with Skp2 siRNA transfection and curcumin treatment. C. The wound healing assay was conducted to detect the cell migration in glioma cells after Skp2 siRNA transfection and curcumin treatment. SiRNA: Skp2 siRNA; Both: curcumin + Skp2 siRNA. *P < 0.05, vs control; #P < 0.05 vs curcumin treatment or Skp2 siRNA transfection. D. Invasion assay was performed in glioma cells after Skp2 siRNA transfection and curcumin treatment.
DISCUSSION
In our present study, we found that curcumin inhibited cell growth and induced cell cycle arrest and apoptosis in U251 and SNB19 glioma cells. We further demonstrated that curcumin suppressed cell migration and invasion in glioma cell. Mechanistically, our findings demonstrated that curcumin exerts its anti-tumor functions through down-regulating Skp2 expression in glioma cells. These results revealed that curcumin could be an effective agent for treating glioma.
Multiple studies have demonstrated that Skp2 has an essential oncogenic function in the pathogenesis of glioma [33–35]. For example, Skp2 was diffusely or focally expressed in most glioblastomas, whereas Skp2 expression was absent or very low in well differentiated astrocytomas [33]. In keep of this concept, increased levels of Skp2 was observed in 31% GBM patients and was associated with shorter overall survival [35]. Therefore, inactivation of Skp2 could block development and progression of glioma. Indeed, down-regulation of Skp2 caused cell growth arrest and apoptosis in T98G glioblastoma cells [34]. In line with these findings, our data validated that inhibition of Skp2 retarded the cell growth, migration, and invasion, but induced cell apoptosis. Consistently, overexpression of Skp2 enhanced cell growth and cell motility in U251 and SNB19 cells.
Due to oncogenic function of Skp2 in glioma, inactivation of Skp2 could be a promising strategy for the treatment of glioma. To this end, several compounds have been discovered to inhibit the expression of Skp2. It has been reported that butylidenephthalide, isolated from Angelica sinensis, down-regulated Skp2 expression and subsequently increased p16 and p21 expressions, leading to cell senescence in human glioblastoma multiform [36]. Additionally, oncostatin M has been found to inhibit the Skp2 levels in glioblastoma cells [37]. Notably, Compound A has been discovered to block Skp2 E3 ligase activity [38]. It has been reported that Skp2 could be inhibited by caffeic acid phenethyl ester and curcumin in cancer cell lines [39–42]. Recently, Compound 25, also known as SZL-P1–41, was developed as a Skp2 inhibitor and inhibited Akt-mediated glycolysis and induced cellular senescence [31]. These inhibitors could have side effects in clinical trials. Due to non-toxic nature, inhibiting Skp2 by nature agents could be a safer approach for treating glioma. In this study, our results demonstrated that curcumin inhibited Skp2 expression in glioma cell lines. We further validated that curcumin exerts its anti-tumor function partly through down-regulation of Skp2. These findings indicated that curcumin may be a useful agent for achieving better treatment of human glioma.
Figure 7: The expression of Skp2 and its targets was measured in Skp2 siRNA transfected glioma cells treated with curcumin. A–B. The expression of Skp2 and its targets including p57 and pAkt was detected by western blotting in glioma cells with Skp2 siRNA transfection and curcumin treatment. C–D. Quantitative results are illustrated for panel A and panel B, respectively. *P < 0.05, vs control; #P < 0.05 vs curcumin treatment or Skp2 siRNA transfection.
Emerging evidence has shown that Akt can directly bind to Skp2 and phosphorylate its serine 72, leading to the translocation of Skp2 from the nucleus to cytoplasm and activation of oncogenic function of Skp2 [27, 43]. However, one study found that Akt drives Skp2 and FOXO1 to the cytoplasm [44, 45]. Further study demonstrated that Skp2 triggered Akt activation in human breast cancer [30]. In support of this note, we observed that Skp2 increased Akt activation in U251 and SNB19 glioma cells. Moreover, curcumin inhibited Skp2 target gene expression including Akt and p57. One study has shown that FoxM1 (Forkhead box protein M1) activated the expression of Skp2 in glioblastoma [46]. Curcumin was reported to suppress FoxM1 expression in human acute myeloid leukemia (AML) [47]. It is possible that curcumin down-regulated Skp2 expression due to inhibition of FoxM1. However, further investigation is required to explore this possibility. It is noteworthy to note that the therapeutic use of curcumin is hampered because of its rapid metabolism and poor absorption. It has been suggested that 2–20 μM curcumin for cancer cell lines, 50–200 mg/kg curcumin for mouse treatment, and 8–12 g/day for human trial were utilized [48–50]. Without a doubt, it is necessary to improve the bioavailable of curcumin and to overcome the blood-brain barrier. It is also required to determine whether curcumin exerts its anti-cancer function through inhibiting Skp2 expression in glioam mouse models in vivo. In conclusion, our studies provided that the inhibition of cell growth, induction of cell apotposis and cell cycle arrest, suppression of cell invasion and migration in glioma cell by curcumin could be partly through down-regulation of Skp2, suggesting that inhibiting Skp2 by curcumin could be an potential effective approach to treat glioma.
MATERIALS AND METHODS
Cell culture and reagents
Human glioma lines U251 and SNB19 were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin in a 5% CO2 atmosphere at 37°C. Primary antibodies for Skp2 and P57 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-pAkt (S473) was purchased from Cell Signaling Technology. All secondary antibodies were purchased from Thermo Scientific. Lipofectamine 2000 was purchased from Invitrogen. Monoclonal anti-β-actin, curcumin (CAS number 458-37-7, 99.5% curcumin) and MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide) were obtained from Sigma-Aldrich (St. Louis, MO). Curcumin was dissolved in DMSO to make a 30 mM stock solution and was added directly to the media at different concentrations. Cells were treated with 0.1% DMSO as the control group.
MTT assay
Cells were seeded at 5 × 103 cells/well in 96-well plate for 24 h and treated with different concentrations of curcumin. After 48 h and 72 h, 10μl of the MTT (5 mg/ml) solution was added to each well and incubated for 4 h at 37°C. Then, the supernatant was absorbed and 100 μl DMSO was added to dissolve the MTT-formazan crystals. The absorption was measured by the microplate at 490 nm.
Cell apoptosis analysis
Cells (1 × 105 cells/well) were cultured in six-well plate overnight and treated with various concentration of curcumin for 48 h. Then, cells were harvested and washed with PBS, resuspended in 500μl binding buffer with 5 μl Propidium iodide (PI) and 5 μl FITC-conjugated anti-Annexin V antibody. Apoptosis was analyzed with a FACScalibur flow cytometer (BD, USA).
Cell cycle analysis
Exponentially growing cells (2 × 105 cells/well) were seeded in a 6-well plate overnight and then treated with 10 μM and 15 μM curcumin for 48 h. After 48 h, cells were collected and washed with cold PBS. Then, suspended cells with 70% cold alcohol were kept at 4°C overnight. Prior to analysis, the cells were washed with cold PBS, and re-suspended at 1 × 106 cells/ml in PBS. Cells were incubated with 0.1 mg/ml RNase I and 50 mg/ml Propidium iodide (PI) at 37°C for 30 min. Cell cycle was analyzed with a FACScalibur flow cytometer (BD, USA).
Cell scratch assays
U251 cells and SNB19 cells were cultured in 6-well plate. After cells converged almost 100%, absorbed the supernatant and scratched the cells with a yellow pipette tips. Then washed the cells with PBS and added medium with curcumin. The scratched area was photographed with a microscope at 0 h and 20 h, respectively, as described before [51].
Cell invasion assay
Cell invasion assay was conducted to test the invasive activity of U251 and SNB19 cells treated with curcumin or Skp2 transfection or combination [51]. Briefly, transfected cells were seeded in the upper chamber with 200 μl serum-free medium and there is 500 μl complete medium in the under chamber with the same concentration of curcumin. After incubation for 24 h, the membrane of the chamber was strained with Giemsa and photographed with a microscope.
Transfection
Cells were seeded into 6-well plate and transfected with Skp2 cDNA or Skp2 siRNA or empty vector using lipofectamine 2000 following the instruction’s protocol [52]. Skp2 siRNA: sense 5′-GGA GUG ACA AAG ACU UUG UTT-3′; antisense 5′-ACA AAG UCU UUG UCA CUC CTT-3′. After the transfection, the cells were subjected to further analysis as described under the results sections.
Quantitative real-time reverse transcription-PCR analysis
The total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA) and reversed-transcribed into cDNA by RevertAid First Strand cDNA Synthesis Kit. PCR were performed using Power SYBR Green PCR Master Mix and the results were calculated by 2-ΔΔCt method as described previously [52]. The primers used in the PCR reaction are: Skp2, forward primer (5′-GCT GCT AAA GGT CTC TGG TGT-3′) and reverse primer (5′-AGG CTT AGA TTC TGC AAC TTG-3′); GAPDH, forward primer (5′-ACC CAG AAG ACT GTG GAT GG-3′) and reverse primer (5′-CAG TGA GCT TCC CGT TCA G-3′).
Western blotting analysis
The harvested cells were washed by PBS and lysed with protein lysis buffer. The concentrations of the proteins were tested by BCA Protein Assay kit (Thermo Scientific, MA). Same amount of protein samples were separated by electrophoresis in Sodium Dodecyl Sulfonate (SDS)-polyacrylamide gel and then transferred onto a Polyvinylidene Fluoride (PVDF) membrane, and then incubated with primary antibody at 4°C overnight. After washed with TBST for three times and incubated with second antibody at room temperature for one hour. Then the expression of protein was detected by electrochemiluminescence (ECL) assay.
Statistical analysis
All statistical analyses were conducted using GraphPad Prism 4.0 (Graph Pad Software, La Jolla, CA). Student’s t-test was performed to evaluate statistical significance. Results were presented as means ± SD. P < 0.05 was considered as statistically significant.
ACKNOWLEDGMENTS
This work was supported by grant from National Natural Science Foundation of China (NSFC 81172087) and a project funded the priority academic program development of Jiangsu higher education institutions.
CONFLICTS OF INTEREST
The authors declare that they have no conflict of interest.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015; 65:5–29.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009; 10:459–466.
3. Walbert T, Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat Res. 2015; 163:171–184.
4. Aggarwal BB, Deb L, Prasad S. Curcumin Differs from Tetrahydrocurcumin for Molecular Targets, Signaling Pathways and Cellular Responses. Molecules. 2014; 20:185–205.
5. Zanotto-Filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, Schroder R, Simoes-Pires A, Battastini AM, Moreira JC. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem. 2012; 23:591–601.
6. Weissenberger J, Priester M, Bernreuther C, Rakel S, Glatzel M, Seifert V, Kogel D. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1, 2/STAT3 signaling pathway. Clinical cancer research. 2010; 16:5781–5795.
7. Bangaru ML, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res. 2010; 30:499–504.
8. Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, Sacchetti P, Focaccetti C, Bernardini R, Tresoldi I, Izzi V, Mattei M, Frajese GV, Lista F, Modesti A, Bei R. Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget. 2014; 5:10745–10762.
9. He M, Li Y, Zhang L, Li L, Shen Y, Lin L, Zheng W, Chen L, Bian X, Ng HK, Tang L. Curcumin suppresses cell proliferation through inhibition of the Wnt/beta-catenin signaling pathway in medulloblastoma. Oncol Rep. 2014; 32:173–180.
10. Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ, Chen LC, Lei XH, Sun X, Liu X, Wang HB, Li XF, Yang DB, Sun Y, Zhao ZF, Jiang T, Li YL, et al. Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo. CNS Neurosci Ther. 2013; 19:926–936.
11. Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 2013; 32:292–297.
12. Hossain M, Banik NL, Ray SK. Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int. 2012; 61:1102–1113.
13. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer. 2011; 11:144.
14. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer. 2011; 11:136.
15. Chan CH, Morrow JK, Zhang S, Lin HK. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014; 13:679–680.
16. Wang Z, Gao D, Fukushima H, Inuzuka H, Liu P, Wan L, Sarkar FH, Wei W. Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta. 2012; 18251:11–17.
17. Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W. Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2012; 1.
18. Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, Ballard BR, Nakayama KI, Matusik RJ, Chen Z. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget. 2015; 6:771–788.
19. Lee SW, Li CF, Jin G, Cai Z, Han F, Chan CH, Yang WL, Li BK, Rezaeian AH, Li HY, Huang HY, Lin HK. Skp2-Dependent Ubiquitination and Activation of LKB1 Is Essential for Cancer Cell Survival under Energy Stress. Mol Cell. 2015; 57:1022–1033.
20. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A. 1998; 95:11324–11329.
21. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999; 9:661–664.
22. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003; 100:10231–10236.
23. Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP, Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, et al. Acetylation-dependent regulation of Skp2 function. Cell. 2012; 150:179–193.
24. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A. 2005; 102:1649–1654.
25. Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014; 14:233–247.
26. Wang J, Huang Y, Guan Z, Zhang JL, Su HK, Zhang W, Yue CF, Yan M, Guan S, Liu QQ. E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma. Oncotarget. 2014; 5:5591–5601.
27. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009; 11:420–432.
28. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010; 464:374–379.
29. Wang Z, Inuzuka H, Zhong J, Liu P, Sarkar FH, Sun Y, Wei W. Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2. Oncotarget. 2012; 3:1294–1300.
30. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012; 149:1098–1111.
31. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013; 154:556–568.
32. Hao Z, Huang S. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front Biosci (Landmark Ed). 2015; 20:474–490.
33. Schiffer D, Cavalla P, Fiano V, Ghimenti C, Piva R. Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett. 2002; 328:125–128.
34. Lee SH, McCormick F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl). 2005; 83:296–307.
35. Saigusa K, Hashimoto N, Tsuda H, Yokoi S, Maruno M, Yoshimine T, Aoyagi M, Ohno K, Imoto I, Inazawa J. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 2005; 96:676–683.
36. Huang MH, Lin SZ, Lin PC, Chiou TW, Harn YW, Ho LI, Chan TM, Chou CW, Chuang CH, Su HL, Harn HJ. Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. Tumour biology. 2014; 35:4875–4884.
37. Halfter H, Friedrich M, Resch A, Kullmann M, Stogbauer F, Ringelstein EB, Hengst L. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res. 2006; 66:6530–6539.
38. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008; 111:4690–4699.
39. Huang HC, Lin CL, Lin JK. 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-23 and BT474 cells through downregulation of Skp2 protein. J Agric Food Chem. 2011; 59:6765–6775.
40. Jia T, Zhang L, Duan Y, Zhang M, Wang G, Zhang J, Zhao Z. The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway. Cancer Cell Int. 2014; 14:126.
41. Sun SH, Huang HC, Huang C, Lin JK. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur J Pharmacol. 2012; 690:22–30.
42. Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, Wang HD, Chuu CP. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015.
43. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009; 11:397–408.
44. Wang H, Cui J, Bauzon F, Zhu L. A comparison between Skp2 and FOXO1 for their cytoplasmic localization by Akt1. Cell Cycle. 2010; 9:1021–1022.
45. Zhang H. Skip the nucleus, AKT drives Skp2 and FOXO1 to the same place? Cell Cycle. 2010; 9:868–869.
46. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R, Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006; 66:3593–3602.
47. Zhang JR, Lu F, Lu T, Dong WH, Li P, Liu N, Ma DX, Ji CY. Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells. J Mol Med (Berl). 2014; 92:1319–1330.
48. Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol. 2014; 20:9384–9391.
49. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol Adv. 2014; 32:1053–1064.
50. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014; 46:2–18.
51. Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen S, Wu Q, Chen C, Wang Z. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015; 6:3268–3279.
52. Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng L, Shi Y, Wang H, Yin B, Xia J, Wang Z. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 2015; 6:1740–1749.
